biopharmaceutical News
-
NeuroScientific Biopharmaceuticals Investor Webinar Presentation – ShareCafe Small Cap “Hidden Gems”
NeuroScientific Biopharmaceuticals Director of Operations, Dr Alexandra Andrews provided an overview of the Company’s peptide-based drug for the treatment of neurodegenerative conditions and an update on the Company's progress towards clinical trials. To see video, please click ...
-
Investor Update from NSB Chairman Paul Rennie
NeuroScientific Biopharmaceuticals Chairman, Paul Rennie provides an investor update to discuss the recent rejection of the Company's HREC submission. To see video, please click ...
-
NeuroScientific’s Director of Operations, Dr Alexandra Heaton Interview with Gareth Quinn of Republic PR
Dr Alexandra Heaton, Director of Operations at NeuroScientific Biopharmaceuticals sat down with Gareth Quinn of Repulbic PR to discuss the recent announcements at the Gold Coast Investor Showcase Conference - June, 2021 To see video, please click here ...
-
AFR: NeuroScientific targets Alzheimer’s cure
NeuroScientifc Biopharmaceuticals says the $5 million it's seeking to raise will fast track the development of an Alzheimer's treatment that the biotech reckons could be "one of the greatest drugs ever". ...
-
Fresenius Kabi completes majority stake acquisition of mAbxience Holding S.L., significantly enhancing presence in high-growth biopharmaceuticals market
A further milestone for Fresenius Kabi’s Vision 2026 growth strategy as the company invests on the core growth vector “Broaden in Biopharma” The combination of both companies positions Fresenius Kabi for accelerated medium- and long-term growth building on a highly complementary product offering in one of the fastest-growing areas of healthcare Enables entry into high-growth ...
By mAbxience
-
Interview with NeuroScientific Biopharmaceuticals CEO and MD Matt Liddelow
Biotech company NeuroScientific Biopharmaceuticals is on the cutting-edge of developing pharmaceutical solutions for neurological disorders and is dedicated to world-class science that improve patient's lives Biotech company NeuroScientific Biopharmaceuticals is on the cutting-edge of developing pharmaceutical solutions for neurological disorders and is dedicated to world-class science that ...
-
mAbxience II Biosimilar Forum
To drive scientific exchange on biopharmaceuticals and high-quality treatment options, more than 180 physicians, pharmacists, and hospital managers from around the world came together in a global conference and over 423 attendees via streaming. On October 21, mAbxience, a leading international biopharmaceutical company of which Fresenius Kabi acquired a majority stake, has celebrated its 2nd ...
By mAbxience
-
Sage Therapeutics to Present at the Stifel 2022 Healthcare Conference
Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the Stifel 2022 Healthcare Conference on Wednesday, November 16, 2022, at 10:55 a.m. ET in New York, NY. A live webcast of the presentation can be accessed on the Investor page of Sage’s website at ...
-
Sage Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference
Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the Piper Sandler 34th Annual Healthcare Conference on Thursday, December 1, 2022, at 8:00 a.m. ET in New York, NY. A live webcast of the presentation can be accessed on the Investor page of Sage’s website at ...
-
BioPharm Plant Relocation in NJ Safely Completed by R. Baker & Son
R. Baker & Son All Industrial Services recently completed a challenging project for a large biopharmaceutical firm in New Jersey. The project involved the relocation of extremely sensitive and technologically advanced biopharmaceutical equipment, utilized in cGMP-regulated environments, from multiple levels of one building to a newly constructed building across site. The equipment was vital ...
-
Sage Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12, 2022, at 3:40 p.m. ET in New York, NY. A live webcast of the presentation can be accessed on the Investor page of Sage’s website ...
-
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
ARLINGTON, Mass., March 29, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update. ...
-
Symic Bio to Present at the 10th Annual ChinaBio Partnering Forum
SAN FRANCISCO, April 18, 2018 – Symic Bio, a biopharmaceutical company developing novel extracellular matrix targeting drugs, today announced that Rinko Ghosh, President and Chief Business Officer, will present an overview of the company pipeline at the 10 thAnnual ChinaBio Partnering Forum being held April 25-26, 2018, in Suzhou, China. ...
-
Symic Bio to Present at the BioCentury 25th Annual Future Leaders Conference in New York
SAN FRANCISCO, March 15, 2018 – Symic Bio, a biopharmaceutical company developing novel extracellular matrix targeting drugs, today announced that Ken Horne, Chief Executive Officer, will present an overview of the company pipeline at the BioCentury 25 th Annual Future Leaders in the Biotech Industry Conference in New ...
-
Greenwich LifeSciences Announces Suspension of Share Repurchase Program
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, announced that its Board of Directors has suspended the Company’s previously announced share repurchase program. Under the now suspended share repurchase program, the Company repurchased approximately 520,000 shares of common stock for ...
-
Feldan Therapeutics Appoints David J. Mazzo, Ph.D. and Iain D. Dukes, Ph.D. to Board of Directors
Feldan Therapeutics, a biotechnology company that develops therapeutics based on the intracellular delivery of proteins and peptides, announces the appointment of Dr. David J. Mazzo and Dr. Iain D. Dukes as independent members of its board of directors. “We are pleased to welcome Drs. Mazzo and Dukes to our board. They are two highly accomplished biopharmaceutical executives who bring many ...
-
Kala Pharmaceuticals Announces New Commercial and Medicare Coverage for EYSUVIS®
ARLINGTON, Mass., May 03, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that the largest Pharmacy Benefit Manager in the United States has added EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% as ...
-
Diffusion Pharmaceuticals to Participate in the Alliance Global Partners Biotech & Specialty Pharma Conference
Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, will participate in the 2021 Alliance Global Partners Biotech & Specialty Pharma Conference taking place November 10, 2021. Diffusion ...
By CervoMed
-
Kala Pharmaceuticals Announces EYSUVIS® Now Covered on UnitedHealthcare Commercial and Cigna Medicare
ARLINGTON, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that UnitedHealthcare, one of the largest commercial health care plans in the United States, covering approximately 13 million lives, ...
-
Scopus Biopharma Completes Recapitalization Designed To Enhance Shareholder Value
New York, New York, October 18, 2022 – Scopus BioPharma Inc. (Nasdaq: “SCPS”), a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, announced today the completion of a series of related recapitalization transactions designed to enhance shareholder value. These transactions include the elimination of ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you